How to improve pharmacoeconomic data generalisability between different countries.
Pharmacoeconomics arises out of a response to the increasing need for accountability of healthcare money in an international environment, when escalating healthcare costs exert an unsustainable burden on the healthcare system. At present, it is difficult to convince any decision makers, whether at the national or institutional level, to list any new drugs into a formulary for subsidy purpose without providing some sort of 'cost-effectiveness' data. This paper discusses the need for having a consensus on what would make pharmacoeconomic data universally acceptable and deals with the issue of improving pharmacoeconomic data generalisability between different countries.
Shu Chuen
SC
Li
D003362:Cost-Benefit Analysis; D003625:Data Collection; D003659:Decision Making, Organizational; D016527:Drug Costs; D004341:Drug Evaluation / Q000639:trends*; D017850:Economics, Pharmaceutical / Q000639:trends*; D005569:Formularies as Topic; D017408:Guidelines as Topic; D006801:Humans; D007391:International Cooperation; D015203:Reproducibility of Results